Shanda Asset Management Holdings’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Shanda Asset Management Holdings’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-35,278	Closed	-$458K	–	43
2019 Q2	$458K	Hold	35,278	–	–	0.09%	26
2019 Q1	$430K	Hold	35,278	–	–	0.07%	44
2018 Q4	$402K	Hold	35,278	–	–	0.08%	41
2018 Q3	$766K	Hold	35,278	–	–	0.12%	28
2018 Q2	$623K	Hold	35,278	–	–	0.1%	45
2018 Q1	$743K	Hold	35,278	–	–	0.12%	30
2017 Q4	$511K	Buy	+35,278	New	+$545K	0.08%	38

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shanda Asset Management Holdings's ITCI Position: Q3 2019 in Review

Shanda Asset Management Holdings sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2019, closing a stake of 35,278 shares — an estimated $458K sold.

Shanda Asset Management Holdings first reported a position in ITCI in Q4 2017 and held it in 7 quarters. The position peaked at $766K in Q3 2018. 126 funds tracked by Wall St. Rank hold ITCI as of Q3 2019.

Shanda Asset Management Holdings reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2019 after selling out during the quarter.
Shanda Asset Management Holdings sold 35,278 Intra-Cellular Therapies Inc. shares in Q3 2019, an estimated $458K.
Shanda Asset Management Holdings first reported a position in Intra-Cellular Therapies Inc. in Q4 2017 and held it in 7 quarters.
Shanda Asset Management Holdings's Intra-Cellular Therapies Inc. position peaked at $766K in Q3 2018.
126 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2019.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2019, filed 14 Nov 2019.